AstraZeneca has several drugs in late-stage clinical trials that management believes make it worth more than $106 billion. It has 14 compounds to treat various cancers, including thyroid, ovarian and leukemia, in Phase III trials. It also has four cardiovascular and metabolism drugs under development and several drugs targeting infections.At the time of publication, the author held no positions in any of the stocks mentioned. This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts